Membranous Glomerulonephritis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Membranous Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions.
Membranous Glomerulonephritis or membranous nephropathy is an autoimmune glomerular disease that affects the functioning of kidneys. Idiopathic and commonly seen in adults. It leads to nephrotic syndrome characterized by edema, proteinuria, frothy urine. Secondary causes of glomerulonephritis is NSAIDs induced, HBV, SLE, cancer and other infectious diseases. Edema, weight gain, fatigue, proteinuria are the symptoms and is diagnosed by analyzing protein levels in urine, biopsy of kidney, blood picture, GFR rate. Fluid restriction if edema is seen and low salt diet is recommended. If cause is autoimmune immunosuppressants are prescribed and antibiotics and angiotensin receptor blockers (ARBs) and anticoagulant therapy.
The Membranous Glomerulonephritis drugs in development market research report provide comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Membranous Glomerulonephritis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Membranous Glomerulonephritis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Membranous Glomerulonephritis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Membranous Glomerulonephritis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Membranous Glomerulonephritis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alpine Immune Sciences IncApellis Pharmaceuticals Inc
Beijing Puqi Pharmaceutical Technology Co Ltd
Cabaletta Bio Inc
Cerium Pharmaceuticals Inc
Human Immunology Biosciences Inc
ImmunoWork LLC
NovelMed Therapeutics Inc
PlateletBio
The Sydney Children's Hospitals Network
Zai Lab Ltd
Zenyaku Kogyo Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Membranous Glomerulonephritis reports